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A bs tr ac t
Background
In autosomal dominant polycystic kidney disease (ADPKD), aberrant activation of 
the mammalian target of rapamycin (mTOR) pathway is associated with progressive 
kidney enlargement. The drug sirolimus suppresses mTOR signaling.
Methods
In this 18-month, open-label, randomized, controlled trial, we sought to determine 
whether sirolimus halts the growth in kidney volume among patients with ADPKD. 
We randomly assigned 100 patients between the ages of 18 and 40 years to receive 
either sirolimus (target dose, 2 mg daily) or standard care. All patients had an esti-
mated creatinine clearance of at least 70 ml per minute. Serial magnetic resonance 
imaging was performed to measure the volume of polycystic kidneys. The primary 
outcome was total kidney volume at 18 months on blinded assessment. Secondary 
outcomes were the glomerular filtration rate and urinary albumin excretion rate at 
18 months.
Results
At randomization, the median total kidney volume was 907 cm3 (interquartile 
range, 577 to 1330) in the sirolimus group and 1003 cm3 (interquartile range, 574 
to 1422) in the control group. The median increase over the 18-month period was 
99 cm3 (interquartile range, 43 to 173) in the sirolimus group and 97 cm3 (inter-
quartile range, 37 to 181) in the control group. At 18 months, the median total 
kidney volume in the sirolimus group was 102% of that in the control group (95% 
confidence interval, 99 to 105; P = 0.26). The glomerular filtration rate did not differ 
significantly between the two groups; however, the urinary albumin excretion rate 
was higher in the sirolimus group.
Conclusions
In adults with ADPKD and early chronic kidney disease, 18 months of treatment 
with sirolimus did not halt polycystic kidney growth. (Funded by Wyeth and others; 
ClinicalTrials.gov number, NCT00346918.)
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A utosomal dominant polycystic kid­ney disease (ADPKD) is the most frequent hereditary kidney disease and the cause of 
end-stage renal disease in 7 to 10% of all patients 
undergoing dialysis.1­3 The disease is character-
ized by the growth of numerous kidney cysts, 
which leads to progressive destruction of the ad-
jacent renal parenchyma and massive enlargement 
of the kidneys.4 Renal function is often preserved 
until the age of 40 years because functioning 
nephrons undergo compensatory hypertrophy.5 
Subsequently, the glomerular filtration rate (GFR) 
decreases, and end-stage renal disease ensues in 
many patients by the fifth decade. As yet, no treat-
ment is available to delay disease progression.6
The main pathogenic features of ADPKD are 
enhanced tubular-cell proliferation, fluid secre-
tion, and the formation of cysts along all seg-
ments of the nephron.7,8 The mammalian target 
of rapamycin (mTOR) is aberrantly activated in 
cystic epithelia in patients with ADPKD.9 Siroli-
mus inhibits mTOR, and in an orthologous mouse 
model of ADPKD10 and other rodent models of 
polycystic kidney disease,11­18 sirolimus signifi-
cantly improved renal cystic disease. Whether 
sirolimus improves renal cystic disease in humans 
with ADPKD has not been determined. On the 
basis of evidence that mTOR inhibitors were 
highly effective in preclinical studies, we conduct-
ed a randomized, open-label, controlled, single-
center trial, called the Suisse ADPKD study, to test 
whether sirolimus would retard kidney-volume 
growth in adults with ADPKD in the early stages 
of chronic kidney disease.
Me thods
Eligibility
Adults with a diagnosis of ADPKD19 were eligible 
to enroll in the trial if they were between the ages 
of 18 and 40 years and had an estimated creati-
nine clearance of at least 70 ml per minute with 
the use of the Cockcroft–Gault equation.20 The 
major exclusion criteria were an increased level 
of liver enzymes (more than two times the upper 
reference limit), a fasting total cholesterol level 
of more than 8 mmol per liter (309 mg per deci-
liter), a triglyceride level of more than 5 mmol 
per liter (443 mg per deciliter), a white-cell count 
of less than 3000 per cubic millimeter, a platelet 
count of less than 100,000 per cubic millimeter, 
or infection with hepatitis B or C virus or with 
the human immunodeficiency virus.
Trial Design
From March 2006 through March 2010, we stud-
ied patients in the trial at the University Hospital 
Zurich in accordance with the ethical principles of 
the Declaration of Helsinki, the Good Clinical 
Practice guidelines of the International Conference 
on Harmonization, and local regulatory require-
ments. The local medical ethics committee ap-
proved the protocol, which was later published.21 
All patients provided written informed consent.
The manufacturer of sirolimus, Wyeth Switzer-
land (now Pfizer), provided the study drug and an 
unrestricted research grant. The company had no 
role in the design of the trial or in the collection, 
analysis, or interpretation of the data or the writ-
ing of the manuscript. The authors vouch for the 
accuracy and completeness of the reported data 
and the fidelity of this report to the trial protocol 
and statistical analysis plan, which are available 
with the full text of this article at NEJM.org.
Data Collection
Each patient’s total kidney volume was measured 
by means of abdominal magnetic resonance im-
aging (MRI) without the administration of con-
trast material at enrollment and 6 months later 
(just before randomization). Patients with a doc-
umented increase in total kidney volume of more 
than 2% during this run-in phase were randomly 
assigned in a 1:1 ratio to receive either sirolimus 
(target dose, 2 mg daily) or standard care (control 
group). Patients with less than a 2% increase in 
total kidney volume underwent a third measure-
ment of kidney volume after a second 6-month 
period and underwent randomization if the in-
crease in total kidney volume was more than 2% 
during the second run-in phase.
Follow-up visits were scheduled at 3, 6, 9, 12, 
and 18 months after randomization. Sirolimus 
levels were measured at each follow-up visit, and 
the dose was adjusted to achieve steady-state 
levels between 4 and 10 µg per liter. In the siroli-
mus group, four additional visits were scheduled 
during the first 6 months for dose adjustment and 
management of any side effects of sirolimus.
At each visit, measurements of serum creati-
nine (with the use of a modified Jaffe method 
traceable to an isotope-dilution mass spectros-
copy reference), lipids, liver enzymes, and blood 
components were performed, along with mea-
surements of albumin and creatinine in spot urine 
samples. The GFR was estimated with the use of 
the Chronic Kidney Disease Epidemiology Collab-
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oration equation.22 Steady-state levels of sirolimus 
in whole blood were determined by means of 
liquid chromatography–mass spectrometry.
Patients’ adherence to the sirolimus regimen 
was assessed by an electronic system that moni-
tored the date and time of the opening of the 
medication bottle (MEMS, Aardex). Adverse events 
were assessed in all randomly assigned patients 
who underwent at least one follow-up visit and 
were classified according to the National Cancer 
Institute’s Common Terminology Criteria for Ad-
verse Events, version 3.0.23
Imaging
Transaxial unenhanced MRI was performed with 
the use of a 1.5-Tesla system (Signa Echospeed 
Excite HD or HDx, GE Healthcare) and a phased-
array surface coil at randomization and at 6, 12, 
and 18 months. Sequences were acquired with 
the use of breath-hold T1-weighted fast spoiled 
gradient echo without fat suppression and respira-
tory-triggered T2-weighted fast spin echo proto-
cols.24 For measurements of total kidney volume, 
two independent observers performed manual 
segmentation of each polycystic kidney on a dedi-
cated computer workstation (Advantage Windows 
Workstation 4.4, GE Healthcare). Each observer 
was unaware of all clinical data and the findings 
of the other observer, and the measurements were 
performed in random order. At each point in time, 
right and left kidney volumes were summed for 
each patient, and the average of the two observ-
ers’ measurements was used for analysis.
Interim Analysis
After 50% of the patients had completed the first 
6 months in the study, the data and safety moni-
toring board performed a planned interim analy-
sis of the primary outcome. To maintain an overall 
alpha level of 0.05, the O’Brien–Fleming bound-
ary approach was applied with nominal P values 
of 0.005 and 0.048 required to show a significant 
treatment effect in interim and final analyses, 
respectively.25 The board recommended the con-
tinuation of enrollment up to the calculated sam-
ple size.26
Statistical Analysis
Data from patients enrolled in the Consortium 
for Radiologic Imaging Studies of Polycystic Kid-
ney Disease (CRISP) showed an annual increase in 
the mean (±SD) total kidney volume of 64±70 ml 
per year (a relative increase of 5.27±3.92%).27 We 
anticipated recruiting patients with an increased 
rate of progression, since only patients with doc-
umented kidney-volume enlargement were eligible 
for this trial. We assumed an initial total kidney 
volume of 1000 cm3 and an annual increase in 
volume of 6.00±4.75%, which would require a 
sample of 40 patients in each group to provide 
a power of 80% to detect a 50% difference in the 
annual increase with the use of a two-sided alpha 
level of 0.05. To allow for a dropout rate of up to 
20%, we determined that 100 patients should un-
dergo randomization.
The primary efficacy analysis in the protocol 
(percent increase in total kidney volume since 
randomization) was amended in an analysis plan 
prepared in April 2008, since measurement of 
the percent change did not account for chance 
imbalance between groups at randomization, and 
the mean percent change was not necessarily 
normally distributed (for details, see the Statisti-
cal Methods section in the Supplementary Ap-
pendix at NEJM.org). An analysis of covariance 
of the log10 total kidney volume at the end of the 
trial, with adjustment for the log10 total kidney 
volume at randomization as a covariate, was used 
to appropriately adjust for any chance imbalance 
between groups at randomization and to provide 
a more precise estimate of the effect of treat-
ment. The least-squares mean difference between 
the groups on the log10 scale was then back-
transformed to provide a sirolimus-to-control 
ratio. Since the distribution of log10-transformed 
total kidney volume was approximately normal 
(Fig. 1 in the Supplementary Appendix), this ratio 
reflects the multiplicative effect of treatment on 
the median total kidney volume in the control 
group. For the four patients with missing values 
for total kidney volume at 18 months, a conser-
vative nominal value was assigned, assuming an 
increase from randomization that was equal to 
either the upper quartile increase in the siro-
limus group (two patients) or the lower quartile 
increase in the control group (two patients). In a 
planned additional efficacy analysis, the covari-
ates of age, sex, and urinary albumin excretion 
rate at randomization were added to the analy-
sis-of-covariance model.
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Secondary outcomes (GFR and log10-trans-
formed urinary albumin excretion rate) were 
analyzed in the same manner but with missing 
values replaced by carrying the last observation 
forward (in the case of three patients for the 
GFR and four patients for the urinary albumin 
excretion rate). SAS software, version 9.1.3, was 
used for analyses, and R, version 2.10.1, for 
graphics, with the default locally weighted scat-
terplot smoothing function in R used to esti-
100 Underwent randomization
133 Underwent first magnetic resonance imaging
8 Withdrew informed consent
265 Patients were screened for autosomal
dominant polycystic kidney disease
132 Were excluded
74 Did not have polycystic kidney disease
29 Withdrew informed consent
29 Did not meet inclusion criteria
25 Were ineligible owing to age
3 Were ineligible owing to creatinine
clearance
1 Was ineligible owing to medical
history
125 Underwent second magnetic resonance
imaging
25 Were excluded
15 Did not have kidney volume enlarge-
ment during the second run-in phase
5 Withdrew informed consent
2 Had hepatitis B infection
2 Did not meet inclusion criteria for
creatinine clearance
1 Was ineligible owing to acute hydro-
nephrosis
50 Were assigned to the
sirolimus group
50 Were assigned to the 
control group
2 Withdrew participation 2 Withdrew participation
50 Were included in the intention-
to-treat analysis
50 Were included in the intention-
to-treat analysis
Figure 1. Enrollment and Outcomes.
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mate a nonparametric mean response curve for 
the outcome in each group over time.28
R esult s
Patients
From March 2006 through March 2008, a total of 
265 patients were screened, and 100 patients 
were recruited and randomly assigned to the si-
rolimus group (50 patients) or the control group 
(50 patients) (Fig. 1). Of these patients, 82 had an 
increase in total kidney volume of more than 2% 
during the first run-in period, and 18 had such 
enlargement during the second run-in period; 33 
patients underwent screening twice. At random-
ization, the characteristics of the patients were 
similar in the two groups (Table 1).
Patients were in early stages of chronic kid-
ney disease: 94% of those in the sirolimus group 
and 98% of those in the control group had a 
GFR of 60 ml or more per minute per 1.73 m2 of 
body-surface area. The median follow-up time 
was 19 months (interquartile range, 18 to 20) in 
the two groups. Four patients (two in each group) 
withdrew from the study; one of the patients in 
the sirolimus group withdrew before receiving a 
first dose of sirolimus and was lost to follow-up. 
All 100 randomized patients were included in the 
intention-to-treat analysis, as specified in the 
protocol.
Total Kidney Volume
At randomization, the median total kidney volume 
was 907 cm3 (interquartile range, 577 to 1330) in 
the sirolimus group and 1003 cm3 (interquartile 
range, 574 to 1422) in the control group (Table 2). 
During the 18-month study period, the median 
total kidney volume increased by 99 cm3 (inter-
quartile range, 43 to 173) in the sirolimus group 
and 97 cm3 (interquartile range, 37 to 181) in the 
control group. At 18 months, the median total 
kidney volume in the sirolimus group was 102% 
of that in the control group (95% confidence in-
terval [CI], 99 to 105; P = 0.26). The ratio of total 
kidney volume in the sirolimus group to total 
volume in the control group remained constant 
throughout the trial (Fig. 2). Annual rates of 
growth in total kidney volume were 9.7% in the 
sirolimus group and 9.5% in the control group 
between enrollment and randomization and 7.8% 
in the sirolimus group and 6.8% in the control 
group between randomization and 18 months.
Estimates of the sirolimus-to-control ratio for 
kidney volume at 18 months were almost identi-
Table 1. Characteristics of the Patients at Randomization.*
Characteristic
Sirolimus 
(N = 50)
Control  
(N = 50)
Age — yr 31±7 32±6
Sex — no. (%)
Female 21 (42) 18 (36)
Male 29 (58) 32 (64)
Race — no. (%)†
White 50 (100) 49 (98)
Black 0 1 (2)
Weight — kg 76±15 75±15
Body-mass index‡ 25±4 24±3
Chronic kidney disease stage — no. (%)§
1 29 (58) 25 (50)
2 18 (36) 24 (48)
3 3 (6) 1 (2)
Blood pressure — mm Hg
Systolic 130±14 130±15
Diastolic 84±11 83±10
Hypertension — no. (%) 36 (72) 32 (64)
Antihypertensive treatment — no. (%)
Any 27 (54) 23 (46)
Angiotensin-converting–enzyme inhibi-
tor or angiotensin-receptor blocker
22 (44) 21 (42)
Diuretic 4 (8) 9 (18)
Other 7 (14) 5 (10)
Previous symptoms or complications 
of ADPKD — no. (%)¶
Flank pain 16 (32) 29 (58)
Macrohematuria 8 (16) 14 (28)
Cyst infection 2 (4) 10 (20)
Intracranial bleeding 1 (2) 1 (2)
≥2 symptoms or complications 6 (12) 15 (30)
* Plus–minus values are means ±SD. ADPKD denotes autosomal dominant 
polycystic kidney disease.
† Race was self-reported.
‡ The body-mass index is the weight in kilograms divided by the square of the 
height in meters.
§ Chronic kidney disease was classified according to the Kidney Disease Out-
comes Quality Initiative of the National Kidney Foundation. Stage 1  denotes  
a glomerular filtration rate (GFR) of 90 ml or more per minute per 1.73 m2  
of body-surface area, stage 2 a GFR of 60 to 89 ml per minute, and stage 3  
a GFR of 30 to 59 ml per minute.
¶ Listed are patients’ self-reported symptoms and complications of ADPKD be-
fore randomization.
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cal in the per-protocol analysis, as well as in one 
planned and one unplanned additional analyses 
of total kidney volume (Table 1 in the Supple-
mentary Appendix). In the planned additional 
analysis, there was no significant between-group 
difference in total kidney volume according to 
age, sex, or albumin-to-creatinine ratio at ran-
domization. At randomization, 43 patients were 
receiving an angiotensin-converting–enzyme (ACE) 
inhibitor or an angiotensin-receptor blocker 
(ARB) (22 in the sirolimus group and 21 in the 
control group), and most of these patients con-
tinued using the drugs. In the unplanned addi-
tional analysis, there was no significant be-
tween-group difference in total kidney volume 
among patients who were taking either an ACE 
inhibitor or an ARB, nor was there any evidence 
that the sirolimus-to-control ratio for kidney 
volume differed if patients were treated with 
these drugs.
At randomization, the median total cyst vol-
ume was 559 cm3 (interquartile range, 240 to 
902) in the sirolimus group and 551 cm3 (inter-
quartile range, 263 to 959) in the control group. 
Over the 18-month treatment period, the total 
cyst volume increased by a median of 74 cm3 
(interquartile range, 3 to 168) in the sirolimus 
group and 59 cm3 (interquartile range, 21 to 142) 
in the control group. The increase in the median 
total noncystic kidney volume from randomiza-
Table 2. Total Kidney Volume, Glomerular Filtration Rate (GFR), and Urinary Albumin-to-Creatinine Ratio  
from Enrollment to 18 Months.*
Outcome Sirolimus (N = 50) Control (N = 50)
Median total kidney volume (interquartile range) — cm3†
Enrollment 875 (591 to 1252) 987 (558 to 1753)
Randomization 907 (577 to 1330) 1003 (574 to 1422)
6 mo 974 (635 to 1466) 1053 (599 to 1549)
12 mo 1003 (668 to 1563) 1109 (618 to 1599)
18 mo 1007 (670 to 1593) 1123 (582 to 1731)
Change from randomization to 18 mo 99 (43 to 173) 97 (37 to 181)
Estimated GFR — ml/min per 1.73 m2‡
Enrollment 92±18 92±17
Randomization 92±20 91±17
6 mo 93±19 89±18
12 mo 91±21 88±19
18 mo 92±21 87±20
Change from randomization to 18 mo 0.2±9.0 −3.5±10
Median urinary albumin-to-creatinine ratio  
(interquartile range)§
Enrollment 2.1 (1.1 to 4.2) 2.1 (1.4 to 5.0)
Randomization 2.2 (0.9 to 4.2) 2.9 (1.0 to 5.2)
6 mo 3.1 (1.2 to 6.8) 2.3 (1.2 to 4.4)
12 mo 3.1 (1.5 to 6.5) 2.8 (0.8 to 5.8)
18 mo 3.4 (1.1 to 7.0) 2.0 (1.1 to 5.0)
Change from randomization to 18 mo 1.1 (−0.3 to 3.0) 0.0 (−0.8 to 0.9)
* Plus –minus values are means ±SD. CI denotes confidence interval.
† For total kidney volume, the sirolimus-to-control adjusted ratio at 18 months was 1.02 (95% CI, 0.99 to 1.05; P = 0.26).
‡ For the GFR, the adjusted difference between the sirolimus group and the control group at 18 months was 3.5 (95% CI, 
−0.3 to 7.4; P = 0.07). The GFR was estimated with the use of the Chronic Kidney Disease Epidemiology Collaboration 
equation.22
§ For the urinary albumin-to-creatinine ratio, the sirolimus-to-control adjusted ratio at 18 months was 1.38 (95% CI, 0.99 
to 1.91; P = 0.05). In this ratio, albumin was measured in milligrams per liter and creatinine in millimoles per liter.
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tion to 18 months was similar in the two groups: 
23 cm3 (interquartile range, −18 to 89) in the 
sirolimus group and 27 cm3 (interquartile range, 
−9 to 93) in the control group.
Estimated GFR and Albuminuria
At 18 months, the adjusted between-group dif-
ference in estimated GFR was 3.5 ml per minute 
per 1.73 m2 (95% CI, −0.3 to 7.4; P = 0.07). The 
difference between the two groups remained 
constant throughout the trial (Fig. 2 in the Sup-
plementary Appendix). However, at 18 months, 
the median ratio of urinary albumin to creati-
nine in the sirolimus group was 138% of that in 
the control group (95% CI, 99 to 191; P = 0.05). 
The ratio between the two groups increased 
steadily during the trial (Fig. 3 in the Supplemen-
tary Appendix).
Sirolimus Dose, Steady-State Drug Levels,  
and Adherence
After the initial dose-adjustment phase, the mean 
sirolimus dose and sirolimus steady-state blood 
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Figure 2. Total Kidney Volume.
The black curves in the center of the plot show nonparametric mean re-
sponse curves for the sirolimus group and the control group, calculated 
with the use of the default locally weighted scatterplot smoothing function 
in R, version 2.10.1. The red and blue curves show measurements from a 
random sample of 10 patients in each study group. The vertical line indi-
cates the planned duration of the trial.
Table 3. Adverse Events in the Safety-Analysis Population.*
Adverse Event Sirolimus (N = 49) Control (N = 50)
no. of patients (%) no. of events (%) no. of patients (%) no. of events (%)
Any adverse event 49 (100) 624 (100) 50 (100) 333 (100)
Infection†
Any 47 (96) 131 (21) 42 (84) 124 (37)
Urinary tract infection 5 (10) 11 (2) 7 (14) 16 (5)
Pain‡
Any 36 (73) 92 (15) 40 (80) 85 (26)
Gastrointestinal
Any 46 (94) 248 (40) 26 (52) 55 (17)
Mucositis 40 (82) 161 (26) 7 (14) 11 (3)
Diarrhea 30 (61) 41 (7) 15 (30) 26 (8)
Skin
Any 35 (71) 56 (9) 12 (24) 13 (4)
Acne 29 (59) 41 (7) 8 (16) 9 (3)
Pulmonary or upper respiratory
Any 13 (27) 16 (3) 3 (6) 3 (1)
Cough 11 (22) 14 (2) 3 (6) 3 (1)
Neurologic
Any 9 (18) 10 (2) 7 (14) 9 (3)
Allergy
Any 7 (14) 7 (1) 7 (14) 7 (2)
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levels remained stable throughout the trial (Table 
2 in the Supplementary Appendix). The mean ad-
herence to the sirolimus regimen, which was 
measured as a percentage of the correct dose, 
was 97% for the entire treatment period (Fig. 4 in 
the Supplementary Appendix).
Blood Pressure and Antihypertensive Therapy
After randomization, the mean systolic and dia-
stolic blood pressures remained stable in both 
groups (Table 3 in the Supplementary Appendix). 
The numbers of patients with hypertension who 
initiated antihypertensive treatment were similar 
in the two groups, with ACE inhibitors and ARBs 
being the most common form of treatment (Ta-
ble 4 in the Supplementary Appendix).
Adverse Events
The overall incidence of adverse events and of 
serious adverse events was similar in the two 
groups (Table 3). The total number of patients 
with gastrointestinal adverse events was higher 
in the sirolimus group (94%) than in the control 
group (52%). The most common gastrointestinal 
adverse events were oral mucositis (in 82% of pa-
tients in the sirolimus group and 14% of those in 
the control group) and diarrhea (61% and 30% of 
patients, respectively). Peripheral edema occurred 
in 16% of patients in the sirolimus group but in 
none of those in the control group. One patient 
in the sirolimus group withdrew at 9 months be-
cause of fatigue. At 18 months, triglyceride and 
cholesterol levels were higher among patients in 
Table 3. (Continued.)
Adverse Event Sirolimus (N = 49) Control (N = 50)
no. of patients (%) no. of events (%) no. of patients (%) no. of events (%)
Constitutional symptom
Any 11 (22) 12 (2) 3 (6) 3 (1)
Fatigue 5 (10) 5 (1) 0 0
Musculoskeletal
Any 5 (10) 9 (1) 9 (18) 10 (3)
Cardiac
Any 6 (12) 6 (1) 6 (12) 6 (2)
Renal or genitourinary§
Any 3 (6) 3 (<1) 9 (18) 12 (4)
Macrohematuria¶ 3 (6) 3 (<1) 8 (16) 11 (3)
Sexual or reproductive function
Any 8 (16) 13 (2) 2 (4) 2 (1)
Lymphatic
Any 8 (16) 11 (2) 0 0
Peripheral edema 8 (16) 10 (2) 0 0
Any serious adverse event‖ 4 (8) 4 (1) 2 (4) 2 (1)
* The safety-analysis population consisted of all randomized patients who underwent at least one follow-up visit. Adverse 
events affecting 5% or more of patients in either study group were described and graded according to the National 
Cancer Institute’s Common Terminology Criteria for Adverse Events, version 3.0. Many patients reported multiple ad-
verse events; only the first event of each category is recorded. Serious adverse events were defined as those resulting in 
hospitalization or disability.
† The most frequently reported infections were upper respiratory infection, bronchitis, and urinary tract infection, and the 
frequency was similar in the two groups.
‡ The most frequently reported types of pain were flank pain, headache, musculoskeletal pain, and abdominal pain, and 
the frequency was similar in the two groups.
§ Nephrolithiasis was not reported in either group.
¶ Macrohematuria was associated with urinary tract infection in two patients in the sirolimus group and one patient in 
the control group. Two episodes of macrohematuria were associated with urinary tract infection in the two groups.
‖ A work accident, febrile gastritis, genitourinary surgery, and facial surgery were reported as serious adverse events in 
the sirolimus group. Jaw surgery and depression were reported as serious adverse events in the control group.
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the sirolimus group (Table 5 in the Supplemen-
tary Appendix).
Discussion
In this study, we aimed to determine whether 
treatment with sirolimus would slow kidney 
growth in patients with ADPKD who had pro-
gressive disease. We found no significant differ-
ence in total kidney volume after 18 months of 
treatment with sirolimus, regardless of the pa-
tient’s age, sex, or albumin:creatinine ratio at 
randomization or whether they were receiving 
therapy with an ACE inhibitor or an ARB. Our 
estimate of the ratio of kidney volume in the si-
rolimus group to that in the control group rules 
out any clinically meaningful reduction in total 
kidney volume with the use of sirolimus. On the 
basis of the lower boundary of the 95% confi-
dence interval for this ratio, 18 months of treat-
ment with sirolimus would at best reduce a me-
dian total kidney volume of 1100 cm3 by 11 cm3.
The magnitude of kidney-volume expansion 
in patients with ADPKD is thought to be the best 
predictor of the subsequent decline in GFR.27 
The discrepancy between the steady increase in 
cyst volume and the delayed decline in renal 
function is an intrinsic difficulty in efforts to 
assess the effect of a treatment on ADPKD. As-
sessing treatment through its effect on the GFR 
would require either trials involving patients 
with advanced disease or a considerable period 
of follow-up. Measurement of the increase in 
kidney or cyst volume is the most practical sur-
rogate test of the effect of a treatment at an 
early stage of the disease.
Our trial was not designed to assess the effect 
of sirolimus on the GFR. As expected, the GFR 
declined only slightly in the control group, but it 
remained stable in the sirolimus group, most 
likely reflecting a sirolimus-associated change in 
glomerular hemodynamics.29 Albuminuria is an 
established predictor of disease progression, and 
approximately 40% of our patients had microal-
buminuria at randomization. There was a slight 
increase in albuminuria in the sirolimus group, 
also presumably reflecting a known side effect 
of the drug.30
The results of this trial contrast with pre-
clinical data, which showed significant benefits 
of mTOR inhibition in rodent models of polycys-
tic kidney disease.9­13,16 Studies in rodent mod-
els of ADPKD, including an orthologous mouse 
model of human ADPKD, have shown that 
mTOR inhibition effectively reduces disease pro-
gression. However, the mTOR inhibitors were 
primarily used in rodent models of early-onset 
or rapidly progressive disease at early stages of 
cyst development. These models may not appro-
priately reflect the more complex and heteroge-
neous pathogenesis of ADPKD in humans, in 
whom the disease progresses slowly over several 
decades and the mechanism of cyst growth is 
not yet understood.31 Our results have to be in-
terpreted in the context of the trial setting, and 
it is possible that sirolimus treatment in adoles-
cence, for a longer period, or in combination 
with other therapies could delay the progression 
of ADPKD.
It is possible that sirolimus had no effect 
because of a suboptimal dose. The achieved si-
rolimus dose was approximately 25% lower than 
the intended dose of 2 mg per day, mainly be-
cause of dose-limiting side effects. Higher doses 
of sirolimus increase the frequency of side ef-
fects,32 and it is likely that adherence to treat-
ment would suffer. The measurement of adher-
ence with the use of electronic devices showed 
that patients in the sirolimus group took 97% of 
the intended dose throughout the trial, making 
nonadherence an unlikely explanation for the 
negative results.
In conclusion, in a randomized, controlled 
trial of an 18-month course of oral sirolimus for 
adults with ADPKD and early chronic kidney 
disease, we found no evidence that sirolimus 
slowed polycystic kidney growth. Our results 
suggest that oral sirolimus as used in this trial 
is not effective in patients with ADPKD at an 
early stage of the disease.
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